U.S. Pharmaceuticals & Biotech Stable Growth Stocks

Incyte

Market Cap: US$20.9b

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Gilead Sciences

Market Cap: US$155.3b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Stevanato Group

Market Cap: US$4.6b

Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

Neurocrine Biosciences

Market Cap: US$16.2b

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Agilent Technologies

Market Cap: US$35.8b

Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.

Vericel

Market Cap: US$2.0b

A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.

Krystal Biotech

Market Cap: US$10.0b

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

Veracyte

Market Cap: US$4.3b

Operates as a diagnostics company in the United States and internationally.

Aurinia Pharmaceuticals

Market Cap: US$2.1b

A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.

ACADIA Pharmaceuticals

Market Cap: US$3.9b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Exelixis

Market Cap: US$12.9b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

TG Therapeutics

Market Cap: US$7.6b

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Medpace Holdings

Market Cap: US$14.6b

Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.

United Therapeutics

Market Cap: US$23.1b

Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Catalyst Pharmaceuticals

Market Cap: US$3.8b

A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.

Bristol-Myers Squibb

Market Cap: US$113.4b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Eli Lilly

Market Cap: US$987.2b

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

Zoetis

Market Cap: US$32.2b

Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Sotera Health

Market Cap: US$4.5b

Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.